logo

Last Update

This profile was last updated on 9/13/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Andrew Griffiths?

Andrew Griffiths

Scientific Founder

HiFiBiO

HQ Phone:  (617) 863-3679

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

HiFiBiO

700 Main St

Cambridge, Massachusetts, 02139

United States

Company Description

HiFiBiO's platform employs paired bar coding, next generation sequencing and rapid DNA synthesis coupled to high throughput cloning and expression enabling single cell-based screening of entire antibody-secreting B cell populations . Identification of diverse ...more

Find other employees at this company (21)

Background Information

Employment History

Director of the Laboratory of Biological Chemistry At the Institut De Science Et d'Ingénierie Supramoléculaires

Université Louis Pasteur


Scientific Founder

BioMillenia


Expert In Droplet Biochemistry

Medical Research Center


Affiliations

Plasticell Ltd

Scientific Advisory Board Member


RainDance Technologies Inc

Founder


Education

Ph.D.


PhD

Molecular Biology

University of Leicester


Web References(36 Total References)


HiFiBiO: High Fidelity Biology | Your Partners In Antibody Biodiscovery

Prof. Andrew Griffiths
Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris. more Prof Griffiths is formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995). This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.


HiFiBiO: High Fidelity Biology | Your Partners In Antibody Biodiscovery

Prof. Andrew Griffiths
Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris. more Prof Griffiths is formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995). This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.


HiFiBiO

Prof. Andrew Griffiths
Andrew Griffiths is a Professor of Biochemistry at Ecole Superieure de Physique et Chimie Industrielle de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995). This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.


Scientific Founders | HiFiBiO: High Fidelity Biology

Prof. Andrew Griffiths
Andrew Griffiths Andrew Griffiths Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995). This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.


Gordon Research Conferences - 2004 Meeting - Biocatalysis

Andrew Griffiths, MRC Laboratory of Molecular Biology


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory